DSIP
Also known as Delta Sleep-Inducing Peptide, Emideltide
A neuropeptide studied for sleep and stress modulation, with old and inconsistent human data.
Medically reviewed by Dr. Jonathan Snipes, MD
Reviewed for clinical accuracy · Last reviewed July 22, 2026 · Review policy
Quick answer
DSIP (delta sleep-inducing peptide, also called emideltide) is a naturally occurring neuropeptide studied for sleep and stress, but the human data is old and inconsistent. It is not FDA-approved, and its compounding pathway was under FDA review at the July 2026 PCAC meeting.
- Type
- Neuropeptide
- FDA status
- Not approved; compounding under review
- Human evidence
- Old and inconsistent
- Evidence grade
- D (Preclinical Only)
- Banned in sport
- Not specifically listed
Key takeaways
- →DSIP was first described decades ago and named for its association with delta-wave sleep.
- →Human research is sparse, old, and produced mixed results; it never became an established sleep therapy.
- →It is not FDA-approved, and modern controlled trials are lacking.
- →DSIP was reviewed at the July 2026 PCAC meeting for the 503A compounding list.
DSIP is a small neuropeptide first identified in research on sleep, from which it takes its name. Despite an intriguing origin story, it is one of the weaker-evidenced peptides on this list: the human studies are decades old, small, and inconsistent, and it never translated into an approved therapy for sleep or anything else.
How DSIP works
DSIP is thought to influence sleep regulation and stress-hormone pathways, and it has been studied in the context of pain and stress as well as sleep. The exact mechanism is not well established, and the older experimental findings have not been reproduced in modern controlled trials.
What the evidence shows, by use
Each use is graded on the same A-E scale, based on human-trial quality rather than popularity.
Sleep
DPreclinical OnlyOlder human studies produced mixed results; there is no modern randomized trial establishing DSIP as an effective sleep aid.
Stress and pain modulation
EAnecdotalExplored in older research, but current controlled human evidence is essentially absent.
Dosing
There is no FDA-approved DSIP product and no validated modern human dose. Circulating protocols come from community practice, not current trials. Because supply is largely unregulated research-grade material, any use should be through a licensed clinician and legitimate pharmacy rather than research-chemical vendors.
Side effects
- •Injection-site reactions · Reported
- •Headache or grogginess · Reported
- •Dizziness · Reported
Legal & regulatory status
DSIP is not FDA-approved. Its compounding pathway was under FDA review at the July 2026 PCAC meeting, where the agency recommended against listing.
Is DSIPlegal? Full regulatory status →Where to get it: TeleRanked independently ranks the telehealth providers that offer clinician-prescribed peptides. See our Peptide Therapy rankings. We rank providers, we do not sell compounds, and rankings are never for sale.
Frequently asked questions
Does DSIP help you sleep?+
The evidence is weak. Older human studies were small and inconsistent, and there is no modern controlled trial establishing DSIP as an effective sleep aid.
Is DSIP FDA-approved?+
No. DSIP is not FDA-approved, and its compounding status was under FDA review at the July 2026 PCAC meeting.
How we grade evidence
Grade D: Preclinical Only. Evidence is largely limited to animal or laboratory studies; human data is minimal or absent. Our A-E scale reflects the strength of human evidence, not how popular a compound is.
Sources
- 1.July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee · U.S. Food & Drug Administration
- 2.Compounding and the FDA: Questions and Answers · U.S. Food & Drug Administration